Jan Basile to Male
This is a "connection" page, showing publications Jan Basile has written about Male.
Connection Strength
0.243
-
ASH 2015 Annual Primary Care Program: What you missed by not attending. J Am Soc Hypertens. 2015 Nov; 9(11):831-6.
Score: 0.029
-
Analysis of recent papers in hypertension treatment of hypertension in the setting of acute intracerebral hemorrhage: still no clear answer on the best BP level to intervene or what BP goal to achieve. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):1-3.
Score: 0.025
-
Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. J Clin Hypertens (Greenwich). 2011 Mar; 13(3):162-9.
Score: 0.021
-
Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens (Greenwich). 2010 Oct; 12(10):809-12.
Score: 0.020
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2004 Feb; 6(2):96-101.
Score: 0.013
-
A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
Score: 0.013
-
Uncontrolled Hypertension in an Elderly Man on Multiple Antihypertensive Drugs. Hypertension. 2020 12; 76(6):1658-1663.
Score: 0.010
-
Combination agents as a means of improving adherence and other aspects of the sixth Joint National Committee Report. South Med J. 2000 May; 93(5):534-6.
Score: 0.010
-
Hypertension and Its Complications in a Young Man With Autoimmune Disease. Hypertension. 2017 04; 69(4):536-544.
Score: 0.008
-
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension. 2016 10; 68(4):888-95.
Score: 0.008
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.007
-
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014 Nov; 29(11):1475-83.
Score: 0.007
-
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT. Clin Nephrol. 2013 Oct; 80(4):235-48.
Score: 0.006
-
Analysis of recent papers in hypertension. Initial combination therapy provides more prompt blood pressure control and reduces cardiovascular events but remains underutilized. J Clin Hypertens (Greenwich). 2013 Aug; 15(8):523-5.
Score: 0.006
-
Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis. J Clin Invest. 1993 Apr; 91(4):1396-8.
Score: 0.006
-
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):20-31.
Score: 0.006
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29; 362(17):1575-85.
Score: 0.005
-
Does prehypertension represent an increased risk for incident hypertension and adverse cardiovascular outcome? Hypertension. 2009 Nov; 54(5):954-5.
Score: 0.005
-
Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol Alcohol. 2009 Sep-Oct; 44(5):464-7.
Score: 0.005
-
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009 Jul; 22(7):792-801.
Score: 0.005
-
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008 Oct; 10(10):751-60.
Score: 0.004
-
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008 Sep; 52(3):412-24.
Score: 0.004
-
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008 Jan 28; 168(2):207-17.
Score: 0.004
-
Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):879-86.
Score: 0.004
-
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
Score: 0.004
-
A trial of education, prompts, and opinion leaders to improve prescription of lipid modifying therapy by primary care physicians for patients with ischemic heart disease. Qual Saf Health Care. 2005 Aug; 14(4):258-63.
Score: 0.004
-
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004 Mar; 6(3):116-25.
Score: 0.003
-
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001 Apr; 24(4):654-8.
Score: 0.003